@article{774421c81dd649d2ab3dd9e9eae2b63f,
title = "Treatment of rheumatoid arthritis in the USA: Premature use of tumor necrosis factor inhibition and underutilization of concomitant methotrexate",
abstract = "Purpose: The objective of this study was to assess the treatment for patients with rheumatoid arthritis (RA) in the USA. Patients and methods: This study entailed analysis of claims data for patients with RA who initiated treatment with oral methotrexate (MTX) or a biologic in 2009 (n=48,910) or 2012 (n=107,636) and had follow-up for 4 years (2009 cohort) or 2 years (2012 cohort). Results: A biologic was initiated before MTX for 27% of the 2009 cohort and 36% of the 2012 cohort. Concomitant use of MTX and a biologic declined from 74.1% (2009 cohort) to 45.4% (2012 cohort). Conclusion: MTX is underused in the treatment of RA in the USA.",
keywords = "Biologic, Claims, Methotrexate, Tumor necrosis factor",
author = "O{\textquoteright}dell, {James R.} and Cohen, {Stanley B.} and {Carter Thorne}, J. and Joel Kremer",
note = "Funding Information: Janssen, Eli Lilly and Company, Medexus, Medac Pharma, Merck, Novartis, and Pfizer. He has been a consultant for AbbVie, Centocor, Sanofi Genzyme, Hospira, Eli Lilly and Company, Medexus, Medac Pharma, and Pfizer. He has been a speaker for Medexus and Medac Pharma. He has received IIS funding from AbbVie, Amgen, and Pfizer, and RCT funding from AbbVie, Celgene, CaREBiodam, Novartis, and Pfizer. Dr Kremer has received research support from AbbVie, Eli Lilly and Company, Novartis, and Pfizer. He has served as a consultant for AbbVie, Bristol-Meyers Squibb, GlaxoSmithKline, Eli Lilly and Company, and Pfizer. He is employed by Corrona. The authors report no other conflicts of interest in this work. Publisher Copyright: {\textcopyright} 2018 O{\textquoteright}Dell et al.",
year = "2018",
doi = "10.2147/OARRR.S169152",
language = "English (US)",
volume = "10",
pages = "97--101",
journal = "Open Access Rheumatology: Research and Reviews",
issn = "1179-156X",
publisher = "Dove Medical Press Limited",
}